Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies

Impact · against what's priced in

Innovent Biologics receives a major valuation catalyst from the closing of a $11.4 billion partnership with Takeda, providing immediate liquidity via a $1.2 billion upfront payment and a high-premium equity investment. Takeda gains access to next-generation IO and ADC therapies, though the impact on its larger market cap is more incremental.

01801+0.90

No priced-in read yet